Xavier Mulet

2.7k total citations · 1 hit paper
34 papers, 1.9k citations indexed

About

Xavier Mulet is a scholar working on Molecular Medicine, Molecular Biology and Pharmacology. According to data from OpenAlex, Xavier Mulet has authored 34 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Medicine, 20 papers in Molecular Biology and 12 papers in Pharmacology. Recurrent topics in Xavier Mulet's work include Antibiotic Resistance in Bacteria (32 papers), Bacterial biofilms and quorum sensing (19 papers) and Antibiotics Pharmacokinetics and Efficacy (12 papers). Xavier Mulet is often cited by papers focused on Antibiotic Resistance in Bacteria (32 papers), Bacterial biofilms and quorum sensing (19 papers) and Antibiotics Pharmacokinetics and Efficacy (12 papers). Xavier Mulet collaborates with scholars based in Spain, Germany and Portugal. Xavier Mulet's co-authors include Carlos Juan, Antonio Oliver, Carla López-Causapé, Gabriel Cabot, Antonio Oliver, José Luis Pérez, Laura Zamorano, Bartolomé Moyá, Pablo A. Fraile-Ribot and Rafael Cantón and has published in prestigious journals such as PLoS ONE, Antimicrobial Agents and Chemotherapy and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Xavier Mulet

34 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The increasing threat of Pseudomonas aeruginosa high-risk clones

2015 478 citations Antonio Oliver, Xavier Mulet et al. Drug Resistance Updates profile →

Peers

Countries citing papers authored by Xavier Mulet

Since Specialization

Citations

This map shows the geographic impact of Xavier Mulet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xavier Mulet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xavier Mulet more than expected).

Fields of papers citing papers by Xavier Mulet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xavier Mulet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xavier Mulet. The network helps show where Xavier Mulet may publish in the future.

Co-authorship network of co-authors of Xavier Mulet

This figure shows the co-authorship network connecting the top 25 collaborators of Xavier Mulet. A scholar is included among the top collaborators of Xavier Mulet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xavier Mulet. Xavier Mulet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Deciphering mechanisms affecting cefepime-taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain 2023 ·European Journal of Clinical Microbiology & Infectious Diseases ·Marta Hernández-García, María García-Castillo, (unknown), Germán Bou, Alain A. Ocampo-Sosa, Cristina Pitart, Irene Gracia-Ahufinger, Xavier Mulet, Álvaro Pascual, Nuria Tormo, Antonio Oliver, Patricia Ruíz-Garbajosa, Rafael Cantón	15
2	In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal 2023 ·Revista Española de Quimioterapia ·Desirée Gijón, María García-Castillo, (unknown), Germán Bou, María Siller, Jorge Calvo, Cristina Pitart, Jordi Vilà, (unknown), (unknown), (unknown), Helena Ramos, Xavier Mulet, Antonio Oliver, Patricia Ruíz-Garbajosa, Rafael Cantón	7
3	Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients 2022 ·Clinical Microbiology and Infection ·Carla López-Causapé, (unknown), María A. Gomis-Font, (unknown), (unknown), Xavier Mulet, Juan de Dios Caballero, Rosa del Campo, Rafael Cantón, Antonio Oliver	23
4	Impact of Peptidoglycan Recycling Blockade and Expression of Horizontally Acquired β-Lactamases on Pseudomonas aeruginosa Virulence 2022 ·Microbiology Spectrum ·Isabel M. Barceló, Gabriel Torrens, (unknown), Elena Jordana‐Lluch, (unknown), (unknown), (unknown), Pablo A. Fraile-Ribot, Xavier Mulet, Antonio Oliver, Carlos Juan	11
5	In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain 2022 ·Antimicrobial Agents and Chemotherapy ·Marta Hernández-García, María García-Castillo, Patricia Ruíz-Garbajosa, Germán Bou, (unknown), Cristina Pitart, Irene Gracia-Ahufinger, Xavier Mulet, Álvaro Pascual, Nuria Tormo, Rafael Cantón	37
6	Role of Enzymatic Activity in the Biological Cost Associated with the Production of AmpC β-Lactamases in Pseudomonas aeruginosa 2022 ·Microbiology Spectrum ·Isabel M. Barceló, Elena Jordana‐Lluch, (unknown), Gabriel Torrens, Pablo A. Fraile-Ribot, Gabriel Cabot, Xavier Mulet, Laura Zamorano, Carlos Juan, Antonio Oliver	11
7	Validation of MALDI-TOF for the early detection of the ST175 high-risk clone of Pseudomonas aeruginosa in clinical isolates belonging to a Spanish nationwide multicenter study 2021 ·Enfermedades infecciosas y microbiologia clinica (English ed ) ·Xavier Mulet, (unknown), (unknown), Laura Zamorano, Ester del Barrio-Tofiño, Antonio Oliver	5
8	Whole-genome sequence-guided PCR for the rapid identification of thePseudomonas aeruginosaST175 high-risk clone directly from clinical samples 2020 ·Journal of Antimicrobial Chemotherapy ·Gabriel Cabot, (unknown), Xavier Mulet, Antonio Oliver	3
9	Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study 2019 ·International Journal of Antimicrobial Agents ·Sergio García‐Fernández, María García-Castillo, Germán Bou, Jorge Calvo, Emilia Cercenado, Mercedes Delgado-Valverde, Cristina Pitart, Xavier Mulet, Nuria Tormo, (unknown), Jazmín Díaz-Regañón, Rafael Cantón	37
10	O-antigen serotyping and MALDI-TOF, potentially useful tools for optimizing semi-empiric antipseudomonal treatments through the early detection of high-risk clones 2019 ·European Journal of Clinical Microbiology & Infectious Diseases ·Xavier Mulet, (unknown), (unknown), Antonio Oliver	21
11	Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands 2018 ·European Journal of Clinical Microbiology & Infectious Diseases ·(unknown), (unknown), Xavier Mulet, (unknown), Pablo A. Fraile-Ribot, Ignacio Ayestarán, A. Colomar, Belén Núñez, María D. Macià, Andrés Novo, Vicente Torres, (unknown), Carla López-Causapé, Olga Delgado Sánchez, José Luis Pérez, Javier Murillas, Melchor Riera, Antonio Oliver	51
12	The increasing threat of Pseudomonas aeruginosa high-risk clones breakdown → 2015 ·Drug Resistance Updates ·Antonio Oliver, Xavier Mulet, Carla López-Causapé, Carlos Juan	478
13	Nosocomial dissemination of VIM-2-producing ST235 Pseudomonas aeruginosa in Lithuania 2015 ·European Journal of Clinical Microbiology & Infectious Diseases ·(unknown), Laura Zamorano, Astra Vitkauskienė, Carla López-Causapé, Carlos Juan, Xavier Mulet, Antonio Oliver	22
14	Genotypic and phenotypic analyses of a Pseudomonas aeruginosa chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains 2015 ·BMC Genomics ·John Varga, Mariette Barbier, Xavier Mulet, Piotr Bielecki, Jennifer Bartell, (unknown), (unknown), Lauren Hittle, Michael R. Davis, F. Heath Damron, George W. Liechti, Jacek Puchałka, Vítor A. P. Martins dos Santos, Robert K. Ernst, Jason A. Papin, Sebastián Albertí, Antonio Oliver, Joanna B. Goldberg	27
15	Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC 2014 ·Antimicrobial Agents and Chemotherapy ·Gabriel Cabot, Sebastian Bruchmann, Xavier Mulet, Laura Zamorano, Bartolomé Moyá, Carlos Juan, Susanne Häußler, Antonio Oliver	193
16	Molecular Epidemiology and Multidrug Resistance Mechanisms of Pseudomonas aeruginosa Isolates from Bulgarian Hospitals 2013 ·Microbial Drug Resistance ·Rossitza Vatcheva-Dobrevska, Xavier Mulet, Ivan Ivanov, Laura Zamorano, Elina Dobreva, (unknown), Todor Kantardjiev, Antonio Oliver	43
17	Clonal Dissemination, Emergence of Mutator Lineages and Antibiotic Resistance Evolution in Pseudomonas aeruginosa Cystic Fibrosis Chronic Lung Infection 2013 ·PLoS ONE ·Carla López-Causapé, Estrella Rojo‐Molinero, Xavier Mulet, Gabriel Cabot, Bartolomé Moyá, Joan Figuerola, Bernat Togores, José L. Pérez, Antonio Oliver	56
18	Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem 2011 ·Journal of Antimicrobial Chemotherapy ·Elena Riera, Gabriel Cabot, Xavier Mulet, María García-Castillo, Rosa del Campo, Carlos Juan, Rafael Cantón, Antonio Oliver	130
19	Antagonistic Interactions of Pseudomonas aeruginosa Antibiotic Resistance Mechanisms in Planktonic but Not Biofilm Growth 2011 ·Antimicrobial Agents and Chemotherapy ·Xavier Mulet, Bartolomé Moyá, Carlos Juan, María D. Macià, José Luis Pérez, Jesús Blázquez, Antonio Oliver	56
20	Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1 2010 ·Journal of Antimicrobial Chemotherapy ·Elena Riera, María D. Macià, A. Mena, Xavier Mulet, José Luis Pérez, (unknown), Antonio Oliver	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact